Immuron shares surge 32.76% premarket after securing DoD-funded oral therapeutics development and pending clinical trial results.

Immuron surged 32.76% in premarket trading following announcements of a U.S. Department of Defense-funded research agreement to develop two oral therapeutics targeting Campylobacter and Shigella pathogens, alongside an update on a pivotal clinical trial evaluating its lead product, Travelan. The collaboration with the Naval Medical Research Command and Walter Reed Army Institute of Research underscores the company’s strategic focus on military applications of its hyper-immune bovine colostrum technology, while anticipation of topline results from the Uniformed Services University’s P2TD study (NCT04605783) further boosted investor confidence. The news reinforces Immuron’s position in addressing high-priority infectious diarrhea treatments, with the DoD funding and clinical trial progress signaling potential for expanded product utility and market access.